Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 12/20 | 0.52 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.46 |
| ▸ | S1PR4 | O95977 | 3/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3267978 | 0.74 | ALDH1A1 (0.52) | CYP1A2TDP1 | |
| SCHEMBL3268412 | 0.73 | CCNB2 (0.43) | — | |
| SCHEMBL15678979 | 0.69 | MAPT (0.47) | MRGPRX4S1PR4CYP1A2TDP1TSHR | |
| SCHEMBL22481017 | 0.68 | MRGPRX4 (1.00) | MRGPRX4ADRB2TDP1 | |
| SCHEMBL25949702 | 0.68 | CYP3A4 (0.34) | — | |
| SCHEMBL22481075 | 0.68 | MRGPRX4 (1.00) | MRGPRX4ADRB2 | |
| SCHEMBL31568543 | 0.68 | MRGPRX4 (1.00) | MRGPRX4ADRB2 | |
| SCHEMBL3736949 | 0.67 | TDP1 (0.56) | MRGPRX4S1PR4TDP1TSHR | |
| SCHEMBL13269603 | 0.67 | ALDH1A1 (0.33) | TSHR | |
| SCHEMBL6644338 | 0.67 | MAPT (0.60) | MRGPRX4ADRB2CYP1A2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1914229-B1 | NOVEL CERCOSPORAMIDE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2010-06-16 | — | — | EP | disclosed |
| US-20090036492-A1 | Novel Cercosporamide Derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-02-05 | — | — | US | disclosed |
| EP-1914229-A1 | NOVEL CERCOSPORAMIDE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036492-A1 | Novel Cercosporamide Derivative | GPR119, CBR3, SLC5A2 | MRGPRX4 191/4885ADRB2 2445/4885S1PR4 1761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.